Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| LSRN Research | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice
Compare Safety, Efficacy and preventative effect of a medical device with a physical mode of action against Nix Cream Rinse (1% Permethrin) in Subjects with Head Lice in a two-arm, randomized, controlled, Investigator/Assessor-blinded comparative study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Medical Device X92001483 | Experimental | Treatment of subjects with head Lice with the standard of care product Nix Creme Rinse on day 0 and day 7, followed by intermediate application of the medical device (X92001483) with a physical mode of action applied every 3 days. |
|
| Nix Cream Rinse (1% Permethrin) | No Intervention | Treatment of subjects with Head Lice with Nix Cream Rinse (1% Permethrin) with a physical mode of action on day 0 and day 7. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Medical Device (X92001483) | Device | Treatment of subjects with Head Lice with a medical device (X92001483) with a physical mode of action on day 0, day 7, day 10, day 13 and day 14. |
| Measure | Description | Time Frame |
|---|---|---|
| Preventative Effect | Determin whether subjects treated with the medical device X92001943 after treatment with Nix Creme Rinse maintain a higher cure rate at the end of the study compared with subjects treated only with Nix Creme Rinse. | 14 days |
| Maintenance of cure rate over time | To assess the maintenance of cure over time: To compare cure rates between subjects treated with Nix Creme Rinse and the medical device X92001483 at interim visits in order to evaluate the presence and persistence of the preventive effect of the investigational product relative to standard of care product (Nix creme rinse) alone. | day 3, day 7, day 10, day 13 and day 14 |
| Measure | Description | Time Frame |
|---|---|---|
| Time to re-infestation | Characterize the time to re-infestation in each treatment group | 14 days |
| Number of live lice | To compare the number of live lice detected at each assessment across treatment groups. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Katie Shepherd | Contact | 561-635-2884 | katie@licesolutions.org |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| LSRN | Recruiting | Maitland | Florida | 32751 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010373 | Lice Infestations |
| ID | Term |
|---|---|
| D004478 | Ectoparasitic Infestations |
| D012876 | Skin Diseases, Parasitic |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D004864 | Equipment and Supplies |
Not provided
Not provided
Not provided
A Two-Arm, Randomized, Controlled, Investigator/Assessor-Blinded, Comparative Study
Not provided
Not provided
Not provided
| Day 0, day 3, day 7, day 10, days 13, day 14 |
| Local tolerability | To evaluate the local tolerability of the standard of care product and investigational product, as measured by subject reported symptoms (eg: burning, paraesthesia, pruritus) following application. | day 0, day 3, day 7, day 10, day 13 and day 14 |
| Scalp and skin irritation | To evaluate scalp and skin irritation by study staff (secondary infection, erythema, excoriation) following product application. | day 0, day 3, day 4, day 7, day 10, day 13 and day 14 |
| Adverse advents | To record and characterize all treatment-emergent adverse events occurring during the study. | Day 0, day 3, day 7, day 10, day 13 and day 14 |
| D012874 |
| Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |